Acambis wins smallpox vaccine case at ITC; appeal looms

Acambis plc (ACM.L) said today that a judge at the International Trade Commission ruled in its favour in its dispute with Bavarian Nordic A/S regarding the latter’s patents related to Modified (smallpox) Vaccinia Ankara ("MVA").

In his order, the judge invalidated all the patent claims asserted by BN against Acambis.

Acambis share price had gained 1.75% by midday to reach 145.50p, valuing the Cambridge-based biotech company at around £154m. By contrast the Denmark-based Bavarian Nordic’s shares had shed around 7%. Acambis gained 10% in July when transcripts suggested the ITC was leaning its way.

Bavarian Nordic filed a complaint with the ITC in August 2005, alleging infringement by Acambis of two of its US MVA patents. It has also filed complaints with the District Court of Delaware and the Commercial Court in Vienna, Austria. An evidentiary hearing was held in May 2006 and the ITC judge has now invalidated each of the patent claims asserted against Acambis and denied BN's request for an exclusionary order. Those invalidated claims are no longer enforceable.

Following the initial determination by the judge, either party (as well as the Commission on its own initiative) can petition for review by a panel of ITC Commissioners who would then make a final determination by early December 2006.

Appeal

Bavarian Nordic said it planned to appeal the judgment.

Acambis Chief Executive Officer Gordon Cameron (pictured) said: "We are delighted with the judge's ruling. It vindicates our long-held view-and the view of several experts in the field-that BN's patents have no merit. Throughout this process, we have strongly asserted our belief in our freedom to operate in the MVA field and it is highly satisfying to have defended this position so successfully.

"We will, of course, be providing this information to the District Court of Delaware, and to both the Commercial Court in Vienna and the European Patent Organisation, where we are opposing BN's European patents."

Regarding the complaint before the District Court of Delaware, the judge has ordered the termination of BN's trade secrets claim, Acambis said in a statement to the London Stock Exchange. As with the ITC decision on the same issue, the termination was based on a question of jurisdiction.

The confidential disclosure agreement that was signed between Acambis and BN in February 2002 contains a mandatory arbitration clause requiring any such disputes between the two companies to be settled in arbitration in Frankfurt, Germany under the rules of the International Chamber of Commerce, the company said.

Acambis and Bavarian are competing for a lucrative contract to supply the vaccine to the US Government. The MVA product is suitable for vulnerable members of the population such as the elderly.

7th September 2006

Previous articles
Light Blue Optics raises $2.5m seed funding from 3i-led consortium
CSR outlays up to $110m on acquisitions to take it into GPS
Briefs: Cambridge Uni, BP to deepen research collaboration; Meldex closes on Dexo sale: Bango wins FT.com account
ARM share price gains as it beats the street with 3Q earnings
CSR enables rapid development of Bluetooth accessories for iPhone
OrthoMimetics, CMI sign licence deal for tissue scalfolding technology to cut joint surgery
CAT, Intercytex lead the way in Biotech Revival
Cash-tight GeneMedix sees restructuring deal done in a 'few weeks'
Silicon Fen Top 20 gains 7.4% in February, pushed along by Alizyme but held back by Plasmon
Market applauds Autonomy’s acquisition of Interwoven Inc for $775m
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • Domino Printing


Nigel R Bond
Group Managing Director


Domino Printing Sciences Plc was founded in 1978. It has established a global reputation for the continual development and manufacture of ink jet and laser printing technologies that set new industry standards in quality and reliability. Its products print variable data such as 'best before' dates,

[Domino Printing's profile]


Top20 Index




Currently: 130.81

Best Deal Mortgages
If debt is becoming a problem, click here for the best deal mortgages.

Marcus Evans conferences
Businesses world-wide trust Marcus Evans for their training courses and conventions!

Scam Events for Marcus Evans
Register for one of the next anti-scam events for Marcus Evans and learn about ethical corporate culture.

IFL
IFL are leaders in the Chrome industry. To find out more visit www.ifml.com